Saturday, July 27, 2013

WE WERE WRONG (Barron's) "Facebook mobile-ad spend crushes our short thesis"

Barron's: A Return Visit To Earlier Stories: What's Next
For Facebook
By Andrew Bary

      (FROM BARRON'S 7/29/13)
      Facebook dealt a big blow to its doubters -- including Barron's -- last
week when it reported its best quarterly results since going public in May 2012.
The company's second-quarter revenue and profit handily topped Wall Street
estimates, prompting a surge of eight points, or 30%, in its share price to
      Facebook's headline earnings of 19 cents a share excluding stock-based
compensation topped the consensus of 14 cents and were up 58% from 12 cents
in the year-earlier period. Revenue gained 53% to $1.8 billion, and mobile-
advertising revenues, the company's focus in recent quarters, totaled $656
million, about $200 million above estimates.
      "We were wrong, Facebook mobile-ad spend crushes our short thesis,"

Sunday, July 21, 2013

Review the free 3-day Equities Trading seminar

Review the free 3-day Equities Trading seminar
View this email in your browser
Juggernaut Trading: Get Started Today

Equities Trading Seminar Recap

Thanks to all who attended this week's free 3-day seminar on Equities Trading (a 599.00 value). If you did not have the chance to attend live or simply want to review what you learned, be sure to watch the recordings while they are still posted.

In these videos Tim & Ben:
  • Review the introduction to our Essential Equities Trading Curriculum
  • Provide an overview of this week's peak earnings reports
  • Explain how the Trader|OS platform can enhance your trading
  • Trade news events LIVE
  • Explain how understanding news events can make you a better trader

Watch the recordings below:

Apple:Cheap Stocks In A Pricey Market (Barron's) Upcoming Earnings

  • expand

    By Jonathan Buck

    The European Union could emerge from recession in the fourth quarter, and enjoy modest economic growth next year. Why Sept. 22 is the date to watch.

Barron's: Cheap Stocks In A Pricey Market
Jul 20 at 00:10
By Andrew Bary

       Even with the Standard & Poor's 500 index at new highs, there still are
plenty of stocks with a single-digit price/earnings ratio.
      Within the S&P 500, about three dozen stocks are valued at less than 10
times projected 2014 earnings; the nearby table identifies 15 low P/E gems. The
single-digit group includes such well-known companies as JPMorgan Chase (ticker:
JPM), Apple (AAPL), Citigroup (C), Deere (DE), General Motors (GM), MetLife
(MET), Prudential Financial (PRU), and Hewlett-Packard (HPQ).

Saturday, July 13, 2013

Check The Buzz On Apple - Peak Earnings Season Kicks Off

  • expand

    By Sandra Ward

    The banking giant's new CEO vows to wring more profit from its global franchise. Asset sales and a tax break should get him there.

Barron's: The Electronic Investor: Check The Buzz On Apple
Jul 13 at 00:03

 Ever wonder what people are saying about your stocks? Tracking
social-media sentiment about companies has become a regular part of portfolio
management for many traders and investors in the last couple of years. If you're
one of them, or just curious, it's definitely worth looking at a new Website
from Market Prophit., which is free while in beta testing, displays
interpretations of conversations taking place on a variety of social media,
delivering bullish and bearish signals to members. It's an intriguing idea,
particularly because the signals are generated in real time, using quantitative

Saturday, July 6, 2013

More Trouble at Linn Energy (Barron's) Earnings Kickoff - Alcoa Reports Monday


By Reshma Kapadia

Multi-asset income funds cast a wide net for yield, and take very different approaches. Here's a look a five of them that have achieved solid returns.

Tuesday, July 2, 2013

$ACHN Notes: OPCO reiterates a Perform Rating - MXIM lowers from Buy

Clinical hold on Achillion drug may not be released,
says Oppenheimer
Jul 2 at 07:50
Profile hits: NONE

      After the FDA placed Achillion's HCV drug sovaprevir on clinical hold
based on its negative interaction with an HIV drug in a study, the firm thinks
the clinical hold may not be released. The firm believes that Achillion will
have trouble finding a partner for sovaprevir, and it reiterates a Perform
rating on the stock.